Dopamine mimics the cardioprotective effect of ischemic preconditioning via activation of α1-adrenoceptors in the isolated rat heart

Physiological Research

Volumn 55, Issue 1, 2006, Pages 1-8

  Lazou, A ^a   Markou, T ^a   Zioga, M ^a   Vasara, E ^a   Efstathiou, A ^a   Gaitanaki, C ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Dopamine; Heart; Ischemia; Preconditioning

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; PRAZOSIN; PROPRANOLOL;

ALPHA ADRENERGIC STIMULATION; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PERFUSION; HEART PROTECTION; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MALE; NONHUMAN; RAT;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; CARDIOTONIC AGENTS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; VENTRICULAR FUNCTION, LEFT;

EID: 33244474214     PISSN: 08628408     EISSN: 08628408     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. AMENTA F, RICCI A, ROSSODIVITA I, AVOLA R, TAYEBATI SK: The dopaminergic system in hypertension. Clin Exp Hypertens 23: 15-24, 2001.
2. ARGAUD L, OVIZE M: How to use the paradigm of ischemic preconditioning to protect the heart? Med Sci 20: 521-525, 2004.
3. 1-adrenergic mechanism. Circ Res 73: 656-670, 1993.
4. BANKWALA Z, HALE SL, KLONER RA: α-Adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catecholamines mimics ischemic preconditioning. Circulation 90: 1023-1028, 1994.
5. 2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol 29: 412-418, 2002.
6. DOGGRELL SA: The therapeutic potential of dopamine modulators on the cardiovascular and renal systems. Expert Opin Investig Drugs 11: 631-644, 2002.
7. EISEN A, FISMAN EZ, RUBENFIRE M, FREIMARK D, MCKECHMIE R, TENENBAUM A, MOTRO M, ADLER Y: Ischemic preconditioning: nearly two decades of research. A comprehensive review. Atherosclerosis 172: 201-210, 2004.
8. EMILIEN G, MALOTEAUX JM, GEURTS M, HOOGENBERG K, CRAGG S: Dopamine receptors - physiological understanding to therapeutic intervention potential. Pharmacol Ther 84: 133-156, 1999.
9. FRYER RM, HSU AK, GROSS GJ: ERK and p38 MAP kinase activation are components of opioid-induced delayed cardioprotection. Basic Res Cardiol 96: 136-142, 2001.
10. GIRBES ARJ, HOOGENBERG K: The use of dopamine and norepinephrine in the ICU. In: Yearbook Intensive Care and Emergency Medicine. J-L VINCENT (ed), Springer, Berlin, 1998, pp 178-187.
11. 2-like receptors in the guinea pig heart. Can J Physiol Pharmacol 80: 578-587, 2002.
12. GOTO M, LIU Y, YANG XM, ARDELL JL, COHEN MV, DOWNEY JM: Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 77: 611-621, 1995.
13. JOSÉ PA, EISNER GM, FELDER RA: Role of dopamine in the pathogenesis of hypertension. Clin Exp Pharmacol Physiol 26 (Suppl): S10-S13, 1999.
14. KRIEG T, QIN Q, MCINTOSH EC, COHEN MV, DOWNEY JM: ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases. Am J Physiol 283: H2322-H2330, 2002.
15. 1 adenosine receptors in rabbit heart. Circulation 84: 350-356, 1991.
16. MITCHELL MB, MENG X, AO L, BROWN JM, HARKEN AH, BANERJEE A: Preconditioning of isolated rat heart is mediated by protein kinase C. Circ Res 76: 73-81, 1995.
17. MURPHY E: Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 94: 7-16, 2004.
18. MURPHY MB: Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 14: S47-S50, 2000.
19. MURRY CE, JENNINGS RB, REIMER KA: Preconditioning with ischemia. A delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
20. NAKANO A, COHEN MV, DOWNEY JM: Ischemic preconditioning: from basic mechanisms to clinical applications. Pharmacol Ther 86: 263-275, 2000.
21. i proteins, phosphatidylinositol 3-kinase and tyrosine kinase. Cardiovasc Res 55: 544-552, 2002.
22. OUEDRAOGO L, MAGNON M, SAWADOGO L, TRICOCHE R: Receptors involved in the positive inotropic action induced by dopamine on the ventricle of a 7-day-old chick embryo heart. Fundam Clin Phamacol 12: 133-142, 1998.
23. OZONO R, O'CONNELL DP, VAUGHAN C, BOTKIN CJ, WALK SF, FELDER RA, CAREY RM: Expression of the subtype 1A dopamine receptor in the rat heart. Hypertension 27: 693-703, 1996.
24. 1 receptor protein in the human heart and kidney. Hypertension 30: 725-729, 1997.
25. 4 receptor in the heart. J Auton Pharmacol 18: 115-121, 1998.
26. SCHWARTZ H-C, CARLSSON A, CARON M, SCATTON B, CIVELLI O, KEBABIAN JW, LANGER SZ, VAN TOL H, SEDVALL G, SEEMAN P, SPANO PF, SOKOLOFF P, VAN TOL H: Dopamine receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification. T GODFRAIND (ed), The Burlington Press, Cambridge, UK, 1998, pp 141-151.
27. SEEMAN P, VAN TOL H: Dopamine receptor pharmacology. Trends Pharmacol Sci 15: 264-270, 1994.
28. SMIT AJ: Dopamine and the kidney. Neth J Med 34: 47-58, 1989.
29. THORNTON JD, DALY JF, COHEN MV, YANG X-M, DOWNEY JM: Catecholamines can induce adenosine receptor-mediated protection of the myocardium but do not participate in ischemic preconditioning in the rabbit. Circ Res 73: 649-655, 1993.
30. 1-Adrenergic receptor agonist-induced preconditioning in isolated working rat hearts. J Pharmacol Exp Ther 273: 689-694, 1995.
31. 1- Adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res 75: 576-585, 1994.
32. 1- adrenoceptors is not essential for the mediation of ischemic preconditioning in rat heart. Clin Exp Pharmacol Physiol 29: 11-17, 2002.
33. VEGH A, PAPP JG, SEMERARO C, FATEHI-HASANABAD Z, PARRATT JR: The dopamine receptor agonist Z1046 reduces ischemia severity in a canine model of coronary artery occlusion. Eur J Pharmacol 344: 203-213, 1998.
34. VELASCO M, LUCHSINGER A: Dopamine: pharmacologic and therapeutic aspects. Am J Ther 5: 37-43, 1998.
35. WU ZK, TARKKA MR, ELORANTA J, PEHKONEN E, KAUKINEN L, HONKONEN EL, KAUKINEN S: Effect of ischemic preconditioning on myocardial protection in coronary artery bypass graft patients: can the free radicals act as trigger for ischemic preconditioning? Chest 119: 1061-1068, 2001.
36. 1A receptor mRNAs in rat heart. Methods Find Exp Clin Pharmacol 18: 183-187, 1996.